Notably, most BRAF-mutated cancers with “very high” TIL/Tc infiltration in the TCGA cohort had stage I or IIA, only one patient had stage IIIC, and none was metastatic, so the hypothesis that an advanced clinical stage could drive the worst prognosis is unlikely. The gene discussed is BRAF; the disease is cancer.